Roivant Sciences (NASDAQ:ROIV) Director Sells $610,245.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 17,750 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.38, for a total transaction of $610,245.00. Following the completion of the sale, the director directly owned 16,474 shares in the company, valued at $566,376.12. This represents a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Trading Down 1.0%

ROIV stock traded down $0.36 during mid-day trading on Wednesday, hitting $35.03. 4,370,640 shares of the company were exchanged, compared to its average volume of 6,139,927. The firm has a fifty day simple moving average of $29.88 and a 200 day simple moving average of $27.02. The company has a market capitalization of $25.20 billion, a PE ratio of -58.38 and a beta of 1.13. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter in the prior year, the business posted ($0.29) EPS. As a group, sell-side analysts anticipate that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ROIV. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. TD Cowen raised their target price on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Citigroup boosted their price target on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Sanford C. Bernstein assumed coverage on shares of Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $33.59.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. SBI Securities Co. Ltd. lifted its stake in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after acquiring an additional 1,166 shares during the period. Allworth Financial LP increased its stake in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Kestra Advisory Services LLC acquired a new position in shares of Roivant Sciences during the fourth quarter valued at approximately $47,000. Parallel Advisors LLC raised its holdings in Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares during the period. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.